A Study of JNJ-99245354 (ITI-1284) as an Adjunctive Treatment in Participants With Generalized Anxiety Disorder (GAD) Who Have an Inadequate Response to GAD Treatment
NCT07856420
This study is recruiting at 4 US sites in 4 states, according to its ClinicalTrials.gov record last updated .
Summary
The purpose of this study is to assess if JNJ-99245354 administered once daily works better to reduce anxiety compared to placebo when given as an additional (adjunctive) therapy in participants with generalized anxiety disorder (GAD; a mental health condition defined by uncontrollable, and excessive worry about everyday events for a long period of time).
Shortened from the sponsor's brief summary. View official record on ClinicalTrials.gov
Conditions studied
- Generalized Anxiety Disorder
Eligibility basics and study details
- Study type
- Interventional
- Phase
- Phase 3
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Sponsor
- Intra-Cellular Therapies, Inc.
- Last updated on ClinicalTrials.gov
- November 3, 2026
These are the basic criteria only. The full inclusion and exclusion criteria are on the official record, and the study team decides who can take part.
US recruiting sites
California · 1
- Inland Psychiatric Medical Group Inc · Temecula, CA
Florida · 1
- Nuovida Research Center · Miami, FL
Massachusetts · 1
- Voltaire Clinical Research · Springfield, MA
New York · 1
- Fieve Clinical Research Inc · New York, NY
Source: ClinicalTrials.gov, data processed . Recruiting US sites filtered by distance and site status; summaries shortened.